Systemic Juvenile Idiopathic Arthritis

Textbook of Pediatric Rheumatology

Volumn , Issue , 2015, Pages 205-216

  De Benedetti, Fabrizio ^a   Schneider, Rayfel ^b,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85167773363     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-24145-8.00016-8     Document Type: Chapter

References (306)

1. R.E. Petty, T.R. Southwood, P. Manners, et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31(2), 390-392
2. E.M. Behrens, T. Beukelman, L. Gallo, et al. (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J. Rheumatol. 35(2), 343-348
3. R.A. Russo and M.M. Katsicas (2013) Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J. Rheumatol. 40(3), 329-334
4. F. De Benedetti, C. Meazza, M. Vivarelli, et al. (2003) Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 48(5), 1398-1407
5. C. Macaubas, K. Nguyen, C. Deshpande, et al. (2010) Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin. Immunol. 134(2), 206-216
6. M.G. Barnes, A.A. Grom, S.D. Thompson, et al. (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60(7), 2102-2112
7. E.M. Ogilvie, A. Khan, M. Hubank, et al. (2007) Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56(6), 1954-1965
8. H.J. van den Ham, W. de Jager, J.W. Bijlsma, et al. (2009) Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) 48(8), 899-905
9. X.B. Ling, J.L. Park, T. Carroll, et al. (2010) Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics 10(24), 4415-4430
10. F. de Benedetti and A. Martini (2005) Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52(3), 687-693
11. F. De Benedetti, N. Rucci, A. Del Fattore, et al. (2006) Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54(11), 3551-3563
12. V. Pascual, F. Allantaz, E. Arce, et al. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486
13. M. Gattorno, A. Piccini, D. Lasiglie, et al. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58(5), 1505-1515
14. D. Holzinger, M. Frosch, A. Kastrup, et al. (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71(6), 974-980
15. M. Yamaguchi, A. Ohta, T. Tsunematsu, et al. (1992) Preliminary criteria for classification of adult Still's disease. J. Rheumatol. 19(3), 424-430
16. E.G. Bywaters and I.C. Isdale (1956) The rash of rheumatoid arthritis and Still's disease. Q. J. Med. 25(99), 377-387
17. J.Y. Lee, C.K. Hsu, M.F. Liu, et al. (2012) Evanescent and persistent pruritic eruptions of adult-onset still disease: a clinical and pathologic study of 36 patients. Semin. Arthritis Rheum. 42(3), 317-326
18. J. Goldenberg, M.B. Ferraz, A.P. Pessoa, et al. (1992) Symptomatic cardiac involvement in juvenile rheumatoid arthritis. Int. J. Cardiol. 34(1), 57-62
19. Y. Kimura, J.E. Weiss, K.L. Haroldson, et al. (2013) Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 65(5), 745-752
20. J. Schaller, B. Beckwith and R.J. Wedgwood (1970) Hepatic involvement in juvenile rheumatoid arthritis. J. Pediatr. 77(2), 203-210
21. N. Ruperto, H.I. Brunner, P. Quartier, et al. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367(25), 2396-2406
22. F. De Benedetti, H.I. Brunner, N. Ruperto, et al. (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367(25), 2385-2395
23. F. Minoia, S. Davi, A. Horne, et al. (2014) Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis A multinational, multicenter study of 362 patients. Arthritis Rheumatol. 66 3160-3169
24. S. Sawhney, P. Woo and K.J. Murray (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child. 85(5), 421-426
25. K.M. Kaufman, B. Linghu, J.D. Szustakowski, et al. (2014) Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol
26. J.L. Stephan, I. Koné-Paut, C. Galambrun, et al. (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40(11), 1285-1292
27. J.I. Henter, A. Horne, M. Arico, et al. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48(2), 124-131
28. A. Ravelli, S. Magni-Manzoni, A. Pistorio, et al. (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146(5), 598-604
29. R. Mouy, J.L. Stephan, P. Pillet, et al. (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J. Pediatr. 129(5), 750-754
30. P.M. Miettunen, A. Narendran, A. Jayanthan, et al. (2011) Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 50(2), 417-419
31. P.J. Kahn and R.Q. Cron (2013) Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J. Rheumatol. 40(5), 743-744
32. K. Immonen, H.A. Savolainen and M. Hakala (2007) Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland? Scand. J. Rheumatol. 36(5), 402-403
33. K. Immonen, A. Savolainen, H. Kautiainen, et al. (2008) Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J. Rheumatol. 35(5), 907-912
34. H.J. Lachmann, H.J. Goodman, J.A. Gilbertson, et al. (2007) Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356(23), 2361-2371
35. C. Giampietro, M. Ridene, T. Lequerre, et al. (2013) Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. (Hoboken) 65(5), 822-826
36. A. Kontzias and P. Efthimiou (2012) The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin. Arthritis Rheum. 42(2), 201-205
37. F. Ortiz-Sanjuán, R. Blanco, V. Calvo-Rio, et al. (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 66(6), 1659-1665
38. H. Wittkowski, M. Frosch, N. Wulffraat, et al. (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58(12), 3924-3931
39. K. Oen, M. Reed, P.N. Malleson, et al. (2003) Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J. Rheumatol. 30(4), 832-840
40. B.A. Lang, R. Schneider, B.J. Reilly, et al. (1995) Radiologic features of systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 22(1), 168-173
41. S. Ringold, P.F. Weiss, T. Beukelman, et al. (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 65(10), 2499-2512
42. P.A. Nigrovic (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 66(6), 1405-1413
43. P.A. Nigrovic, M. Mannion, F.H. Prince, et al. (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63(2), 545-555
44. S.J. Vastert, W. de Jager, B.J. Noordman, et al. (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66(4), 1034-1043
45. N.T. Ilowite, K. Prather, Y. Lokhnygina, et al. (2014) Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 66(9), 2570-2579
46. S. Urien, C. Bardin, B. Bader-Meunier, et al. (2013) Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol. Toxicol. 14 40
47. P. Quartier, F. Allantaz, R. Cimaz, et al. (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70(5), 747-754
48. S. Yokota, T. Imagawa, M. Mori, et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617), 998-1006
49. S. Yokota, T. Imagawa, M. Mori, et al. (2014) Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 41(4), 759-767
50. D.J. Lovell, E.H. Giannini, A. Reiff, et al. (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48(1), 218-226
51. G. Horneff, H. Schmeling, T. Biedermann, et al. (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63(12), 1638-1644
52. R.A. Russo and M.M. Katsicas (2009) Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 36(5), 1078-1082
53. N. Ruperto, D.J. Lovell, P. Quartier, et al. (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792-1802
54. P. Woo, T.R. Southwood, A.M. Prieur, et al. (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 43(8), 1849-1857
55. D.M. Brinkman, I.M. de Kleer, R. ten Cate, et al. (2007) Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 56(7), 2410-2421
56. C. Lomater, V. Gerloni, M. Gattinara, et al. (2000) Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 27(2), 491-496
57. D. Singh-Grewal, R. Schneider, N. Bayer, et al. (2006) Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 54(5), 1595-1601
58. L.R. Spiegel, R. Schneider, B.A. Lang, et al. (2000) Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43(11), 2402-2409
59. C. Modesto, P. Woo, J. García-Consuegra, et al. (2001) Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin. Exp. Rheumatol. 19(2), 211-217
60. P.J. Hashkes, B.M. Wright, M.S. Lauer, et al. (2010) Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 62(2), 599-608
61. Entire reference list is available online at www.expertconsult.com
62. R.E. Petty, T.R. Southwood, P. Manners, et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31(2), 390-392
63. G.F. Still (1897) On a form of chronic joint disease in children. Med. Chir. Trans. 80 47-60.9
64. L. Berntson, B. Andersson Gäre, A. Fasth, et al. (2003) Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J. Rheumatol. 30(10), 2275-2282
65. S. Danner, C. Sordet, J. Terzic, et al. (2006) Epidemiology of juvenile idiopathic arthritis in Alsace, France. J. Rheumatol. 33(7), 1377-1381
66. C. Huemer, M. Huemer, T. Dorner, et al. (2001) Incidence of pediatric rheumatic diseases in a regional population in Austria. J. Rheumatol. 28(9), 2116-2119
67. N. Moe and M. Rygg (1998) Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin. Exp. Rheumatol. 16(1), 99-101
68. B.A. Gäre and A. Fasth (1992) Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 90(6), 950-958
69. S. Fujikawa and M. Okuni (1997) A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr. Jpn. 39(2), 242-244
70. V. Seth, S.K. Kabra, O.P. Semwal, et al. (1996) Clinico-immunological profile in juvenile rheumatoid arthritis—an Indian experience. Indian J. Pediatr. 63(3), 293-300
71. B.M. Feldman, N. Birdi, J.E. Boone, et al. (1996) Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J. Pediatr. 129(4), 513-518
72. C.B. Lindsley (1987) Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 30(7), 838-839
73. D.B. Sullivan, J.T. Cassidy and R.E. Petty (1975) Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritis Rheum. 18(3), 251-255
74. Y. Uziel, A. Pomeranz, R. Brik, et al. (1999) Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J. Rheumatol. 26(5), 1187-1189
75. E.M. Ogilvie, M.S. Fife, S.D. Thompson, et al. (2003) The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 48(11), 3202-3206
76. E.M. Behrens, T. Beukelman, L. Gallo, et al. (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J. Rheumatol. 35(2), 343-348
77. R.A. Russo and M.M. Katsicas (2013) Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J. Rheumatol. 40(3), 329-334
78. D. Fishman, G. Faulds, R. Jeffery, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102(7), 1369-1376
79. Y. Date, N. Seki, S. Kamizono, et al. (1999) Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5´-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum. 42(12), 2577-2582
80. R. Donn, Z. Alourfi, F. De Benedetti, et al. (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 46(9), 2402-2409
81. R.P. Donn, E. Shelley, W.E. Ollier, et al. (2001) A novel 5´-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 44(8), 1782-1785
82. F. De Benedetti, C. Meazza, M. Vivarelli, et al. (2003) Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 48(5), 1398-1407
83. C.J. Stock, E.M. Ogilvie, J.M. Samuel, et al. (2008) Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun. 9(4), 349-357
84. C. Macaubas, K. Nguyen, C. Deshpande, et al. (2010) Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin. Immunol. 134(2), 206-216
85. M.G. Barnes, A.A. Grom, S.D. Thompson, et al. (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60(7), 2102-2112
86. F. Allantaz, D. Chaussabel, D. Stichweh, et al. (2007) Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204(9), 2131-2144
87. S. Ishikawa, T. Mima, C. Aoki, et al. (2009) Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann. Rheum. Dis. 68(2), 264-272
88. E.M. Ogilvie, A. Khan, M. Hubank, et al. (2007) Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56(6), 1954-1965
89. X.B. Ling, C. Macaubas, H.C. Alexander, et al. (2012) Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis. BMC Med. 10 125
90. C. Meazza, P. Travaglino, P. Pignatti, et al. (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum. 46(1), 232-237
91. F. De Benedetti, M. Massa, P. Pignatti, et al. (1995) Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J. Rheumatol. 22(8), 1581-1585
92. F. De Benedetti, P. Pignatti, S. Bernasconi, et al. (1999) Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. J. Rheumatol. 26(2), 425-431
93. H. Mangge, H. Kenzian, S. Gallistl, et al. (1995) Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 38(2), 211-220
94. W. de Jager, E.P. Hoppenreijs, N.M. Wulffraat, et al. (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 66(5), 589-598
95. A.P. Lotito, A. Campa, C.A. Silva, et al. (2007) Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. 34(4), 823-830
96. M. Rooney, J. David, J. Symons, et al. (1995) Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol. 34(5), 454-460
97. H.J. van den Ham, W. de Jager, J.W. Bijlsma, et al. (2009) Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) 48(8), 899-905
98. X.B. Ling, J.L. Park, T. Carroll, et al. (2010) Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics 10(24), 4415-4430
99. F. de Benedetti, P. Pignatti, M. Massa, et al. (1997) Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br. J. Rheumatol. 36(5), 581-588
100. M.A. Muzaffer, J.M. Dayer, B.M. Feldman, et al. (2002) Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J. Rheumatol. 29(5), 1071-1078
101. A.M. Prieur, P. Roux-Lombard and J.M. Dayer (1996) Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rhum. Engl. Ed 63(3), 163-170
102. F. de Benedetti and A. Martini (2005) Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52(3), 687-693
103. F. de Benedetti, M. Massa, P. Robbioni, et al. (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34(9), 1158-1163
104. F. De Benedetti, P. Pignatti, V. Gerloni, et al. (1997) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 24(7), 1403-1409
105. L. Lepore, M. Pennesi, S. Saletta, et al. (1994) Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin. Exp. Rheumatol. 12(5), 561-565
106. P. Pignatti, M. Vivarelli, C. Meazza, et al. (2001) Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J. Rheumatol. 28(7), 1670-1676
107. T. Alonzi, E. Fattori, D. Lazzaro, et al. (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187(4), 461-468
108. F. De Benedetti, T. Alonzi, A. Moretta, et al. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99(4), 643-650
109. F. De Benedetti, N. Rucci, A. Del Fattore, et al. (2006) Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54(11), 3551-3563
110. M. Cazzola, L. Ponchio, F. de Benedetti, et al. (1996) Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87(11), 4824-4830
111. V. Pascual, F. Allantaz, E. Arce, et al. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486
112. M. Frosch, M. Ahlmann, T. Vogl, et al. (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60(3), 883-891
113. M. Gattorno, A. Piccini, D. Lasiglie, et al. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58(5), 1505-1515
114. M. Guma, L. Ronacher, R. Liu-Bryan, et al. (2009) Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 60(12), 3642-3650
115. M. Frosch, T. Vogl, S. Seeliger, et al. (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 48(9), 2622-2626
116. D. Holzinger, M. Frosch, A. Kastrup, et al. (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71(6), 974-980
117. D. Viemann, A. Strey, A. Janning, et al. (2005) Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 105(7), 2955-2962
118. T. Vogl, K. Tenbrock, S. Ludwig, et al. (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13(9), 1042-1049
119. J.C. Möller, D. Paul, G. Ganser, et al. (2010) IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin. Exp. Rheumatol. 28(6), 912-918
120. I. de Kleer, B. Vastert, M. Klein, et al. (2006) Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107(4), 1696-1702
121. M. Yamaguchi, A. Ohta, T. Tsunematsu, et al. (1992) Preliminary criteria for classification of adult Still's disease. J. Rheumatol. 19(3), 424-430
122. E.G. Bywaters and I.C. Isdale (1956) The rash of rheumatoid arthritis and Still's disease. Q. J. Med. 25(99), 377-387
123. J. Schaller and R.J. Wedgwood (1970) Pruritus associated with the rash of juvenile rheumatoid arthritis. Pediatrics 45(2), 296-298
124. T. Avcin, E.D. Silverman, V. Forte, et al. (2005) Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease. J. Rheumatol. 32(12), 2429-2431
125. P.A. Livermore and K.J. Murray (2002) Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford) 41(12), 1450-1452
126. J.Y. Lee, C.K. Hsu, M.F. Liu, et al. (2012) Evanescent and persistent pruritic eruptions of adult-onset still disease: a clinical and pathologic study of 36 patients. Semin. Arthritis Rheum. 42(3), 317-326
127. R.R. Fortna, J.E. Gudjonsson, G. Seidel, et al. (2010) Persistent pruritic papules and plaques: a characteristic histopathologic presentation seen in a subset of patients with adult-onset and juvenile Still's disease. J. Cutan. Pathol. 37(9), 932-937
128. R. Schneider, B.A. Lang, B.J. Reilly, et al. (1992) Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J. Pediatr. 120(2 Pt 1), 200-205
129. B.J. Bloom, L.B. Tucker, L.C. Miller, et al. (1995) Bicipital synovial cysts in juvenile rheumatoid arthritis: clinical description and sonographic correlation. J. Rheumatol. 22(10), 1953-1955
130. M.L. Miller, L. Levinson, L.M. Pachman, et al. (1995) Abnormal muscle MRI in a patient with systemic juvenile arthritis. Pediatr. Radiol. 25(Suppl. 1), S107-S108
131. B. Bernstein, M. Takahashi and V. Hanson (1974) Cardiac involvement in juvenile rheumatoid arthritis. J. Pediatr. 85(3), 313-317
132. J. Scharf, J. Levy, A. Benderly, et al. (1976) Pericardial tamponade in juvenile rheumatoid arthritis. Arthritis Rheum. 19(4), 760-762
133. H.A. Majeed and J. Kvasnicka (1978) Juvenile rheumatoid arthritis with cardiac tamponade. Ann. Rheum. Dis. 37(3), 273-276
134. C.L. Yancey, R.A. Doughty, B.A. Cohlan, et al. (1981) Pericarditis and cardiac tamponade in juvenile rheumatoid arthritis. Pediatrics 68(3), 369-373
135. P.S. Lietman and E.G. Bywaters (1963) Pericarditis in Juvenile Rheumatoid Arthritis. Pediatrics 32 855-860
136. J. Goldenberg, M.B. Ferraz, A.P. Pessoa, et al. (1992) Symptomatic cardiac involvement in juvenile rheumatoid arthritis. Int. J. Cardiol. 34(1), 57-62
137. J.J. Miller 3rd and J.W. French (1977) Myocarditis in juvenile rheumatoid arthritis. Am. J. Dis. Child. 131(2), 205-209
138. D. Oguz, B. Ocal, U. Ertan, et al. (2000) Left ventricular diastolic functions in juvenile rheumatoid arthritis. Pediatr. Cardiol. 21(4), 374-377
139. A.S. Zeft, S.C. Menon and D. Miller (2012) Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist. Pediatr. Rheumatol. Online J. 10 8
140. P.H. Kramer, J.B. Imboden Jr., F.M. Waldman, et al. (1983) Severe aortic insufficiency in juvenile chronic arthritis. Am. J. Med. 74(6), 1088-1091
141. J. Heyd and J. Glaser (1990) Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. Am. J. Med. 89(1), 123-124
142. B.A. Binstadt, J.C. Levine, P.A. Nigrovic, et al. (2005) Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 116(1), e89-e93
143. G.L. Brinkman and L. Chaikof (1959) Rheumatoid lung disease: report of a case which developed in childhood. Am. Rev. Respir. Dis. 80 732-737
144. B.H. Athreya, R.A. Doughty, M. Bookspan, et al. (1980) Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and review. Clin. Chest Med. 1(3), 361-374
145. J.D. Jordan and C.H. Snyder (1964) Rheumatoid disease of the lung and cor pulmonale. Observations in a child. Am. J. Dis. Child. 108 174-180
146. D. Lovell, C. Lindsley and C. Langston (1984) Lymphoid interstitial pneumonia in juvenile rheumatoid arthritis. J. Pediatr. 105(6), 947-950
147. S. Padeh, R.M. Laxer, M.M. Silver, et al. (1991) Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum. 34(12), 1575-1579
148. R. Schultz, J. Mattila, M. Gappa, et al. (2001) Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr. Pulmonol. 32(5), 397-402
149. Y. Kimura, J.E. Weiss, K.L. Haroldson, et al. (2013) Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 65(5), 745-752
150. A. Leber, S. Carette, K.R. Chapman, et al. (2010) A 21-year-old man with systemic-onset juvenile rheumatoid arthritis, cough and progressive dyspnea. Can. Respir. J. 17(3), e42-e44
151. A.V. Ramanan, R.F. Wynn, A. Kelsey, et al. (2003) Systemic juvenile idiopathic arthritis, Kikuchi's disease and haemophagocytic lymphohistiocytosis—is there a link? Case report and literature review. Rheumatology (Oxford) 42(4), 596-598
152. J. Schaller, B. Beckwith and R.J. Wedgwood (1970) Hepatic involvement in juvenile rheumatoid arthritis. J. Pediatr. 77(2), 203-210
153. A.H. Naber, U. Van Haelst and S.H. Yap (1991) Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J. Hepatol. 12(1), 94-99
154. W.A. Sifuentes Giraldo, A. Burdaspal Moratilla, A. Moreno Caparros, et al. (2014) Nodular regenerative hyperplasia of the liver as a complication of long-standing systemic-onset juvenile idiopathic arthritis. Reumatol. Clin. 10(3), 194-195. [Article in English, Spanish]
155. S. Canna, J. Frankovich, G. Higgins, et al. (2009) Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr. Rheumatol. Online J. 7 21
156. N. Ruperto, H.I. Brunner, P. Quartier, et al. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367(25), 2396-2406
157. F. De Benedetti, H.I. Brunner, N. Ruperto, et al. (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367(25), 2385-2395
158. J.C. Jacobs (1985) JRA and hyperphosphataemia. J. Pediatr. 107(5), 828-829
159. G. Lockitch, M.R. Pudek and A.C. Halstead (1984) Isolated elevation of serum alkaline phosphatase. J. Pediatr. 105(5), 773-775
160. M. Hadchouel, A.M. Prieur and C. Griscelli (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr. 106(4), 561-566
161. D.E. Blockmans, D.C. Knockaert and H.J. Bobbaers (2000) Still's disease can cause neutrophilic meningitis. Neurology 54(5), 1203-1205
162. F.J. Garrote, J. Marco, G. Obeso, et al. (1993) Aseptic meningitis and focal central nervous system involvement in a case of adult onset Still's disease. J. Rheumatol. 20(4), 765-767
163. A. Ohta, M. Yamaguchi, T. Tsunematsu, et al. (1990) Adult Still's disease: a multicenter survey of Japanese patients. J. Rheumatol. 17(8), 1058-1063
164. F. Tabak, M. Tanverdi, R. Ozaras, et al. (2003) Neutrophilic pleocytosis in cerebrospinal fluid: adult-onset Still's disease. Intern. Med. 42(10), 1039-1041
165. R. Schneider, E.D. Silverman and B.M. Feldman (2000) 315. Acute fatal neurologic events in severe systemic-onset juvenile rheumatoid arthritis. Plenary session (ACR). Arthritis Rheum. 43 S115-S408
166. I.L. Arroyo, K.S. Barron and E.J. Brewer Jr. (1988) Spinal cord compression by epidural lipomatosis in juvenile rheumatoid arthritis. Arthritis Rheum. 31(3), 447-451
167. R.K. Saurenmann, A.V. Levin, B.M. Feldman, et al. (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 56(2), 647-657
168. A.T. Moore and J.D. Morin (1985) Bilateral acquired inflammatory Brown's syndrome. J. Pediatr. Ophthalmol. Strabismus 22(1), 26-30
169. F.M. Wang, C. Wertenbaker, M.M. Behrens, et al. (1984) Acquired Brown's syndrome in children with juvenile rheumatoid arthritis. Ophthalmology 91(1), 23-26
170. A. Belot, B. Bader-Meunier, P. Niaudet, et al. (2012) ANCA-associated glomerulonephritis in systemic-onset juvenile idiopathic arthritis. Am. J. Kidney Dis. 59(3), 439-443
171. F. Minoia, S. Davi, A. Horne, et al. (2014) Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis A multinational, multicenter study of 362 patients. Arthritis Rheumatol. 66 3160-3169
172. S. Sawhney, P. Woo and K.J. Murray (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child. 85(5), 421-426
173. S.J. Vastert, R. van Wijk, L.E. D’Urbano, et al. (2010) Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49(3), 441-449
174. M.M. Hazen, A.L. Woodward, I. Hofmann, et al. (2008) Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 58(2), 567-570
175. K. Zhang, J. Biroschak, D.N. Glass, et al. (2008) Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 58(9), 2892-2896
176. K.M. Kaufman, B. Linghu, J.D. Szustakowski, et al. (2014) Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol
177. L. Cifaldi, G. Prencipe, I. Caiello, et al. (2014) Inhibition of natural killer (NK) cell cytotoxicity by interleukin-6: implications for the pathogenesis or marcophage activation syndrome. 21st European Pediatric Rheumatology (PReS) Congress, Belgrade, Serbia. 17-21 September 2014. Pediatri. Rheumatol. 12(Suppl. 1), 56
178. T. Avcin, S.M. Tse, R. Schneider, et al. (2006) Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatr. 148(5), 683-686
179. J.L. Stephan, I. Koné-Paut, C. Galambrun, et al. (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40(11), 1285-1292
180. A.A. Grom, J. Villanueva, S. Lee, et al. (2003) Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142(3), 292-296
181. J. Barash, M. Cooper and Z. Tauber (1991) Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin. Exp. Rheumatol. 9(5), 541-543
182. J.C. Jacobs, L.J. Gorin, A.S. Hanissian, et al. (1984) Consumption coagulopathy after gold therapy for JRA. J. Pediatr. 105(4), 674-675
183. P.J. Manners and B.M. Ansell (1986) Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 77(1), 99-103
184. R. Eraso, A. Gedalia and L.R. Espinoza (2002) Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 29(5), 1104. author reply 1104-5
185. A.V. Ramanan and R. Schneider (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 30(2), 401-403
186. A. Ravelli, M.C. Caria, S. Buratti, et al. (2001) Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 28(4), 865-867
187. A. Ravelli, R. Schneider, S. Weitzman, et al. (2014) A56: Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheumatol. 66 S83-S84
188. E.D. Silverman, J.J. Miller 3rd, B. Bernstein, et al. (1983) Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J. Pediatr. 103(6), 872-876
189. A. Ravelli (2002) Macrophage activation syndrome. Curr. Opin. Rheumatol. 14(5), 548-552
190. J.I. Henter, A. Horne, M. Arico, et al. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48(2), 124-131
191. A. Ravelli, S. Magni-Manzoni, A. Pistorio, et al. (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146(5), 598-604
192. K. Lehmberg, I. Pink, C. Eulenburg, et al. (2013) Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J. Pediatr. 162(6), 1245-1251
193. S. Davi, A. Consolaro, D. Guseinova, et al. (2011) An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 38(4), 764-768
194. M. Shimizu, Y. Nakagishi, K. Kasai, et al. (2012) Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 58(2), 287-294
195. R. Mouy, J.L. Stephan, P. Pillet, et al. (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J. Pediatr. 129(5), 750-754
196. B. Quesnel, B. Catteau, V. Aznar, et al. (1997) Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br. J. Haematol. 97(2), 508-510
197. A. Ravelli, F. De Benedetti, S. Viola, et al. (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J. Pediatr. 128(2), 275-278
198. A. Kelly and A.V. Ramanan (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4(11), 615-620
199. N. Bruck, M. Suttorp, M. Kabus, et al. (2011) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheumatol. 17(1), 23-27
200. P.M. Miettunen, A. Narendran, A. Jayanthan, et al. (2011) Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 50(2), 417-419
201. P.J. Kahn and R.Q. Cron (2013) Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J. Rheumatol. 40(5), 743-744
202. U. Emmenegger, U. Frey, A. Reimers, et al. (2001) Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am. J. Hematol. 68(1), 4-10
203. J.J. Calabro (1969) Amyloidosis and juvenile rheumatoid arthritis. J. Pediatr. 75(3), 521
204. T.J. Schnitzer and B.M. Ansell (1977) Amyloidosis in juvenile chronic polyarthritis. Arthritis Rheum. 20(2 Suppl.), 245-252
205. H. Ozdogan, O. Kasapcopur, H. Dede, et al. (1991) Juvenile chronic arthritis in a Turkish population. Clin. Exp. Rheumatol. 9(4), 431-435
206. B.M. Ansell (1999) Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis). J. Rheumatol. 26(4), 765-766
207. J. David, O. Vouyiouka, B.M. Ansell, et al. (1993) Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin. Exp. Rheumatol. 11(1), 85-90
208. H.A. Savolainen and H.A. Isomäki (1993) Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J. Rheumatol. 20(7), 1201-1203
209. K. Immonen, H.A. Savolainen and M. Hakala (2007) Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland? Scand. J. Rheumatol. 36(5), 402-403
210. N.A. Ayaz, S. Ozen, Y. Bilginer, et al. (2009) MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 48(1), 23-25
211. L. Cantarini, O.M. Lucherini, R. Cimaz, et al. (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol. Int. 32(12), 4015-4018
212. K. Immonen, A. Savolainen, H. Kautiainen, et al. (2008) Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J. Rheumatol. 35(5), 907-912
213. H.J. Lachmann, H.J. Goodman, J.A. Gilbertson, et al. (2007) Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356(23), 2361-2371
214. J.D. Gillmore, L.B. Lovat, M.R. Persey, et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358(9275), 24-29
215. J.E. Gottenberg, F. Merle-Vincent, F. Bentaberry, et al. (2003) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 48(7), 2019-2024
216. Y. Okuda and K. Takasugi (2006) Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 54(9), 2997-3000
217. L.C. Miller, B.A. Sisson, L.B. Tucker, et al. (1996) Prolonged fevers of unknown origin in children: patterns of presentation and outcome. J. Pediatr. 129(3), 419-423
218. S. Kumar, B. Vaidyanathan, S. Gayathri, et al. (2013) Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol. Int. 33(4), 1065-1069
219. A. Manki, R. Nishikomori, M. Nakata-Hizume, et al. (2006) Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis. Allergol. Int. 55(3), 337-341
220. K. Sievers, P. Ahvonen, K. Aho, et al. (1963) Serological patterns in juvenile rheumatoid arthritis. Rheumatism 19 88-93
221. R.G. Aptekar, J.L. Decker, J.S. Bujak, et al. (1973) Adult onset juvenile rheumatoid arthritis. Arthritis Rheum. 16(6), 715-718
222. E.G. Bywaters (1971) Still's disease in the adult. Ann. Rheum. Dis. 30(2), 121-133
223. J.J. Cush, T.A. Medsger Jr., W.C. Christy, et al. (1987) Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum. 30(2), 186-194
224. P.J. Roberts-Thomson, T.R. Southwood, B.W. Moore, et al. (1986) Adult onset Still's disease or coxsackie polyarthritis? Aust. N. Z. J. Med. 16(4), 509-511
225. M. Gerfaud-Valentin, Y. Jamilloux, J. Iwaz, et al. (2014) Adult-onset Still's disease. Autoimmun. Rev. 13(7), 708-722
226. L. Fardet, P. Coppo, A. Kettaneh, et al. (2008) Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 58(5), 1521-1527
227. B. Fautrel, G. Le Moël, B. Saint-Marcoux, et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J. Rheumatol. 28(2), 322-329
228. Z. Wang, Y. Wang, J. Wang, et al. (2009) Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. Int. J. Hematol. 90(4), 501-505
229. C. Giampietro, M. Ridene, T. Lequerre, et al. (2013) Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. (Hoboken) 65(5), 822-826
230. D. Nordström, A. Knight, R. Luukkainen, et al. (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J. Rheumatol. 39(10), 2008-2011
231. A. Kontzias and P. Efthimiou (2012) The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin. Arthritis Rheum. 42(2), 201-205
232. K. Laskari, A.G. Tzioufas and H.M. Moutsopoulos (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res. Ther. 13(3), R91
233. F. Ortiz-Sanjuán, R. Blanco, V. Calvo-Rio, et al. (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 66(6), 1659-1665
234. O. Elkayam, N. Jiries, Z. Dranitzki, et al. (2014) Tocilizumab in adult-onset Still's disease: the Israeli experience. J. Rheumatol. 41(2), 244-247
235. P. Cipriani, P. Ruscitti, F. Carubbi, et al. (2014) Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin. Rheumatol. 33(1), 49-55
236. M. Frosch, D. Metze, D. Foell, et al. (2005) Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp. Dermatol. 14(4), 259-265
237. D.D. Sherry and D.W. Kredich (1985) Transient thrombocytopenia in systemic onset juvenile rheumatoid arthritis. Pediatrics 76(4), 600-603
238. A.K. Ewer, P.J. Darbyshire and T.R. Southwood (1993) Systemic-onset juvenile chronic arthritis and bone marrow hypoplasia. Br. J. Rheumatol. 32(1), 78-80
239. R.N. Rubin, B.K. Walker, S.K. Ballas, et al. (1978) Erythroid aplasia in juvenile rheumatoid arthritis. Am. J. Dis. Child. 132(8), 760-762
240. J.J. Miller 3rd, Y.P. Hsu, R. Moss, et al. (1979) The immunologic and clinical associations of the split products of C3 in plasma in juvenile rheumatoid arthritis. Arthritis Rheum. 22(5), 502-507
241. H. Wittkowski, M. Frosch, N. Wulffraat, et al. (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58(12), 3924-3931
242. K. Oen, M. Reed, P.N. Malleson, et al. (2003) Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J. Rheumatol. 30(4), 832-840
243. B.A. Lang, R. Schneider, B.J. Reilly, et al. (1995) Radiologic features of systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 22(1), 168-173
244. S. Ringold, P.F. Weiss, T. Beukelman, et al. (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 65(10), 2499-2512
245. P.A. Nigrovic (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 66(6), 1405-1413
246. P.A. Nigrovic, M. Mannion, F.H. Prince, et al. (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63(2), 545-555
247. S.J. Vastert, W. de Jager, B.J. Noordman, et al. (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66(4), 1034-1043
248. E.M. DeWitt, Y. Kimura, T. Beukelman, et al. (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 64(7), 1001-1010
249. N.T. Ilowite, K. Prather, Y. Lokhnygina, et al. (2014) Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 66(9), 2570-2579
250. W. Breit, M. Frosch, U. Meyer, et al. (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J. Rheumatol. 27(11), 2696-2702
251. S. Urien, C. Bardin, B. Bader-Meunier, et al. (2013) Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol. Toxicol. 14 40
252. P. Quartier, F. Allantaz, R. Cimaz, et al. (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70(5), 747-754
253. A. Zeft, R. Hollister, B. LaFleur, et al. (2009) Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J. Clin. Rheumatol. 15(4), 161-164
254. T. Lequerre, P. Quartier, D. Rosellini, et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67(3), 302-308
255. V. Ohlsson, E. Baildam, H. Foster, et al. (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47(4), 555-556
256. N. Ruperto, P. Quartier, N. Wulffraat, et al. (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64(2), 557-567
257. P. Woo, N. Wilkinson, A.M. Prieur, et al. (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 7(6), R1281-R1288
258. S. Yokota, T. Miyamae, T. Imagawa, et al. (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52(3), 818-825
259. S. Yokota, T. Imagawa, M. Mori, et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617), 998-1006
260. S. Yokota, T. Imagawa, M. Mori, et al. (2014) Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 41(4), 759-767
261. F. De Benedetti, H. Brunner, N. Ruperto, et al. (2012) Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. 2012 EULAR Annual Meeting. Ann. Rheum. Dis. 71(Suppl. 3), 42528
262. F. De Benedetti, N. Ruperto, G. Espada, et al. (2012) Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial. Arthritis Rheum. 64(Suppl. 10), S327
263. C. Malattia, N. Ruperto, E. Palmisani, et al. (2014) A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. Arthritis Rheumatol. 66(Suppl. 11), S96-S97
264. P. Quartier, A. Grom, N. Ruperto, et al. (2014) Efficacy of Canakinumab in biologic naive versus previously biologic-exposed sJIA pateints. Ann. Rheum. Dis. 73(Suppl. 2)
265. F. De Benedetti, H. Brunner, E. Baildam, et al. (2013) Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA) PRCSG and PRINTO 1IRCCS. Pediatr. Rheumatol. Online J. 11(Suppl. 2), 152
266. D.J. Lovell, E.H. Giannini, A. Reiff, et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342(11), 763-769
267. D.J. Lovell, E.H. Giannini, A. Reiff, et al. (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48(1), 218-226
268. G. Horneff, H. Schmeling, T. Biedermann, et al. (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63(12), 1638-1644
269. F.H. Prince, M. Twilt, R. ten Cate, et al. (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis. 68(5), 635-641
270. P. Quartier, P. Taupin, F. Bourdeaut, et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48(4), 1093-1101
271. Y. Kimura, P. Pinho, G. Walco, et al. (2005) Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 32(5), 935-942
272. R.A. Russo and M.M. Katsicas (2009) Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 36(5), 1078-1082
273. N. Ruperto, D.J. Lovell, P. Quartier, et al. (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792-1802
274. J.L. Record, T. Beukelman and R.Q. Cron (2011) Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J. Rheumatol. 38(1), 180-181
275. E.I. Alexeeva, S.I. Valieva, T.M. Bzarova, et al. (2011) Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 30(9), 1163-1172
276. P. Woo, T.R. Southwood, A.M. Prieur, et al. (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 43(8), 1849-1857
277. F. De Benedetti, H. Brunner, R. Allen, et al. (2011) Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial. Arthritis Rheum. 63(Suppl. 10), S1029
278. J.W. Groothoff and E.F. van Leeuwen (1988) High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br. Med. J. (Clin. Res. Ed) 296(6633), 1362-1363
279. A.M. Prieur, A. Adleff, M. Debre, et al. (1990) High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin. Exp. Rheumatol. 8(6), 603-608
280. E.D. Silverman, R.M. Laxer, M. Greenwald, et al. (1990) Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 33(7), 1015-1022
281. Y. Uziel, R.M. Laxer, R. Schneider, et al. (1996) Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J. Rheumatol. 23(5), 910-918
282. E.D. Silverman, G.D. Cawkwell, D.J. Lovell, et al. (1994) Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J. Rheumatol. 21(12), 2353-2358
283. V. Gerloni, R. Cimaz, M. Gattinara, et al. (2001) Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40(8), 907-913
284. N. Ruperto, A. Ravelli, E. Castell, et al. (2006) Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin. Exp. Rheumatol. 24(5), 599-605
285. T.J. Lehman, S.J. Schechter, R.P. Sundel, et al. (2004) Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J. Pediatr. 145(6), 856-857
286. M. Garcia-Carrasco, S. Fuentes-Alexandro, R.O. Escarcega, et al. (2007) Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine 74(5), 500-503
287. J. Vojinovic, N. Damjanov, C. D’Urzo, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63(5), 1452-1458
288. M. Abinun, T.J. Flood, A.J. Cant, et al. (2009) Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol. Immunol. 47(1), 46-51
289. D.M. Brinkman, I.M. de Kleer, R. ten Cate, et al. (2007) Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 56(7), 2410-2421
290. J.J. Calabro, W.B. Holgerson, G.M. Sonpal, et al. (1976) Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin. Arthritis Rheum. 5(3), 257-298
291. F. Fantini, V. Gerloni, M. Gattinara, et al. (2003) Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J. Rheumatol. 30(3), 579-584
292. C. Lomater, V. Gerloni, M. Gattinara, et al. (2000) Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 27(2), 491-496
293. D. Singh-Grewal, R. Schneider, N. Bayer, et al. (2006) Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 54(5), 1595-1601
294. L.R. Spiegel, R. Schneider, B.A. Lang, et al. (2000) Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43(11), 2402-2409
295. S.J. Lin, J.L. Huang, H.C. Chao, et al. (1999) A follow-up study of systemic-onset juvenile rheumatoid arthritis in children. Acta Paediatr. Taiwan. 40(3), 176-181
296. J. van der Net, W. Kuis, A.B. Prakken, et al. (1997) Correlates of disablement in systemic onset juvenile chronic arthritis. A cross sectional study. Scand. J. Rheumatol. 26(3), 188-196
297. C.A. Wallace and J.E. Levinson (1991) Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. 17(4), 891-905
298. K. Minden, U. Kiessling, J. Listing, et al. (2000) Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J. Rheumatol. 27(9), 2256-2263
299. K. Oen, P.N. Malleson, D.A. Cabral, et al. (2002) Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J. Rheumatol. 29(9), 1989-1999
300. C.A. Wallace, B. Huang, M. Bandeira, et al. (2005) Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 52(11), 3554-3562
301. C. Modesto, P. Woo, J. García-Consuegra, et al. (2001) Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin. Exp. Rheumatol. 19(2), 211-217
302. C. Sandborg, T.H. Holmes, T. Lee, et al. (2006) Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol. 33(11), 2322-2329
303. B.J. Bloom, A.J. Alario and L.C. Miller (2009) Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis. J. Rheumatol. 36(2), 422-426
304. J. Baum and G. Gutowska (1977) Death in juvenile rheumatoid arthritis. Arthritis Rheum. 20 253-255
305. B. Bernstein (1977) Death in juvenile rheumatoid arthritis. Arthritis Rheum. 20(Suppl.), 256-257
306. P.J. Hashkes, B.M. Wright, M.S. Lauer, et al. (2010) Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 62(2), 599-608